The 2018 ASCO Clinical Practice Guideline Update also recognized the conflicting evidence surrounding gonadotropin-releasing hormone (GnRH) agonists for fertility preservation and concluded that GnRH agonists may be offered to young women with breast cancer with the goal of reducing chemotherapy-induced ovarian insufficiency when other proven fertility preservation options are not available3. This evidence concerns the gene GNRH1 and breast cancer.